Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2016-12-21 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于第二大股东部分股权质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's second largest shareholder. It details the number of shares pledged, the pledgee, and the purpose of the pledge. There is no financial report, earnings data, or management discussion. The content fits the description of a Major Shareholding Notification, as it informs about changes in significant share ownership levels and related pledges. The document is short and focused on shareholding changes rather than financial results or governance changes.
2016-12-21 Chinese
关于控股子公司获准在全国中小企业股份转让系统挂牌的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding its controlling subsidiary, Liaoning Maidi Biotechnology Co., Ltd., being approved to be listed on the National SME Share Transfer System. It includes details about the approval letter, regulatory exemptions, and the listing process. The document is short (623 characters) and serves as a public notice of a regulatory event related to share transfer and listing status. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, earnings release, or any detailed financial or governance report. It is an official regulatory announcement about a capital market event (listing on a share transfer system). This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-12-01 Chinese
关于多西他赛注射液获得药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a drug registration certificate for a pharmaceutical product. It includes details about the drug, market context, and the impact on the company. The document is short (1246 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-11-24 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Shuanglu Pharmaceutical Co., Ltd. regarding an external investment of 10 million RMB into Beijing Kangming Bio New Drug R&D Co., Ltd. It details the investment amount, purpose, risks, and impact on the company. The text includes board meeting resolutions, independent director opinions, and investment details. There are no financial statements or comprehensive financial performance data. The document is a formal announcement of a capital investment transaction, not a full financial report or earnings release. It fits best under Capital/Financing Update (CAP) as it concerns company fundraising and capital structure changes through investment in another company.
2016-11-15 Chinese
独立董事关于出资1000万元投资北京康明百奥新药研发有限公司参与其增资扩股的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent director's opinion on a proposed investment of 10 million yuan by the company into another entity, Beijing Kangming Bai'ao New Drug R&D Co., Ltd., as part of a capital increase. It references compliance with relevant laws and company procedures and concludes with the independent directors' agreement to the investment proposal. The document is short (686 characters) and focuses on approval and opinion regarding a capital investment decision, not a full financial report or audit. It is not an announcement of a report publication but a formal opinion related to a capital financing activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-11-15 Chinese
第六届董事会第八次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of Beijing SL Pharmaceutical Co., Ltd. regarding a resolution passed in a board meeting to invest 10 million RMB in a new drug R&D company. It details the board meeting date, attendance, and the investment decision. There is no financial report, audit, or earnings data presented. The content focuses on a board decision about investment, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing. Therefore, the classification is MANG with high confidence.
2016-11-15 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.